Cover Image
市場調查報告書

Frontier Pharma:血液癌症 - 極為創新的開發平台持續趨向標靶治療、患者個別療法的趨勢

Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies

出版商 GBI Research 商品編碼 363067
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
Frontier Pharma:血液癌症 - 極為創新的開發平台持續趨向標靶治療、患者個別療法的趨勢 Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies
出版日期: 2016年06月01日 內容資訊: 英文 73 Pages
簡介

本報告提供全球血液癌症及相關疾病的治療藥開發的最新趨勢主要產品的資訊,尤其是First-in-Class (創新藥物)的詳細資訊相關分析,疾病概要和已上市產品的特性,研究開發的進展,開發平台上的First-in-Class與其他產品的比較,目標分子的差異、變化,今後的研究開發、產品上市預測,資本交易、共同開發趨勢等調查。

第1章 目錄

第2章 摘要整理

第3章 血液癌症的革新的案例

  • 生技藥品的市場機會的擴大
  • 分子標的多樣化
  • 創新的First-in-Class產品的開發依然富有魅力
  • 法規、醫療費償付政策喜歡First-in-Class產品革新變化
  • 革新的持續
  • GBI Research的調查指導

第4章 臨床方面、商業方面環境

  • 疾病概要
  • 流行病學
    • 白血病
    • 淋巴瘤
    • 骨髓瘤
  • 病理學
    • 白血病
    • 淋巴瘤
    • 骨髓瘤
  • 症狀
  • 診斷
    • 白血病
    • 淋巴瘤
    • 骨髓瘤
  • 預後、存活率
    • 存活率
  • 治療
    • 手術、放射線治療
    • 幹細胞移植
    • 藥理學性
  • 已上市產品概要
    • 結論
    • 未滿足需求

第5章 開發中產品革新的評估

  • 概要
  • 開發平台:各分子類型,階段及治療標的
  • 血液癌症市場、開發平台間的計劃的分佈比較:治療標的各系列
  • First-in-Class的開發中產品

第6章 血液癌症的病理學、革新的調整

  • 癌症的信號傳達網路的複雜性及First-in-Class分子標的整合
  • 信號傳達途徑,引起疾病的突然變異
  • First-in-Class標的矩陣評估

第7章 First-in-Class標的評估

  • 以白細胞介素7受體為目標的開發平台計劃
  • 以Notch 2、Notch 3為目標的開發平台計劃
  • 以焦點黏合激酶為目標的開發平台計劃
  • 以薄膜相關淋巴組織淋巴瘤轉移蛋白質1為目標的開發平台
  • 以白細胞介素1受體附屬蛋白質為目標的開發平台計劃
  • 以HLA-DR 為目標的開發平台計劃
  • 以L-serekuchin為目標的開發平台計劃
  • 以真核細胞翻譯啟動因子4E為目標的開發平台計劃

第8章 策略性整合

  • 產業規模的First-in-Class契約
  • 授權合約
    • 各地區、年度、金額
    • 各開發階段、金額
    • 各分子類型、分子標的、金額
  • 共同開發契約
    • 各地區、年度、金額
    • 各開發階段、金額
    • 各分子類型、作用機制、金額
  • 授權合約和共同開發都沒包含的First-in-Class計劃

第9章 附錄

圖表一覽

目錄
Product Code: GBIHC394MR

Executive Summary

Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow, and include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating that lymphomas are more prevalent than leukemia or myeloma. Excluding acute lymphocytic leukemia and Hodgkin's lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent.

The report assesses first-in-class innovation in the hematological cancer pipeline, highlighting key trends in first-in-class product distribution. Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry, with 463 first-in-class products, representing 45.3% of the pipeline with a disclosed molecular target.

The first-in-class targets in the pipeline are numerous and varied in nature. Cancer immunotherapies are the most common, with a total of 128 across all stages of development, followed by the signal transduction group of targets. The most commercially successful targeted drugs in the market fall into these two categories, including Rituxan (a cancer immunotherapy) and Gleevec (a signal transducer). The other target families have much fewer first-in-class products, reflecting the strong interest in cancer immunotherapies and targets implicated in signal transduction.

Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies. These developments have been based on the growing understanding of the signaling pathways involved in disease pathogenesis. A notable example is the approval of Rituxan in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin's lymphoma. Analysis indicates that the current pipeline is following this trend of focusing on innovative, targeted therapies.

Scope

The hematological cancers market is characterized by commercially successful therapies.

  • Which classes of drug dominate the market?
  • What additional benefits have newly approved therapies brought to the market?

The pipeline contains a range of molecule types and molecular targets, with a strong emphasis on targeted therapies, as opposed to chemotherapeutic agents.

  • Which molecular targets appear most frequently in the pipeline?
  • To what degree is the pipeline penetrated by first-in-class innovation?
  • Which target families have the most first-in-class products?

First-in-class products differ substantially in their clinical potential, based on their alignment to disease-causing pathways.

  • How well are first-in-class targets aligned to known disease-causing pathways?
  • Which targets are specifically found in early-stage development?
  • Which are the most promising first-in-class targets in early-stage development?

There have been 284 licensing deals and 238 co-development deals pertaining to hematological cancer products since 2006.

  • Which territories show the most deal activity?
  • What were the trends in deal completion by product stage of development?
  • Which of the first-in-class products in development are not currently involved in a licensing or co-development deal, and therefore represent investment opportunities?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
  • Visualize the composition of the hematological cancers market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
  • Analyze the hematological cancers pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating hematological cancers.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
  • Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of hematological cancer therapies that are not yet involved in deals, and may be potential investment opportunities.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Executive Summary

  • 2.1. Significant Unmet Needs Persist in Hematological Cancer Market
  • 2.2. Large Hematological Cancer Pipeline Displays Strong Degree of Innovation
  • 2.3. Leuekmia Displays Most Pipeline Activity among Hematological Cancer Indications

3. The Case for Innovation in Hematological Cancers

  • 3.1. Growing Number of Opportunities for Biologic Products
  • 3.2. Diversification of Molecular Targets
  • 3.3. Innovative First-in-Class Product Developments Remain Attractive
  • 3.4. Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
  • 3.5. Sustained Innovation
  • 3.6. GBI Research Report Guidance

4. Clinical and Commercial Landscape

  • 4.1. Disease Overview
  • 4.2. Epidemiology
    • 4.2.1. Leukemia
    • 4.2.2. Lymphoma
    • 4.2.3. Myeloma
  • 4.3. Pathophysiology
    • 4.3.1. Leukemia
    • 4.3.2. Lymphoma
    • 4.3.3. Myeloma
  • 4.4. Symptoms
  • 4.5. Diagnosis
    • 4.5.1. Leukemia
    • 4.5.2. Lymphoma
    • 4.5.3. Myeloma
  • 4.6. Prognosis and Survival
    • 4.6.1. Survival
  • 4.7. Treatment
    • 4.7.1. Surgery and Radiation Therapy
    • 4.7.2. Stem-Cell Transplantation
    • 4.7.3. Pharmacological
  • 4.8. Overview of Marketed Products
    • 4.8.1. Conclusion
    • 4.8.2. Unmet Need

5. Assessment of Pipeline Product Innovation

  • 5.1. Pipeline by Molecule Type, Phase and Therapeutic Target
  • 5.2. Comparative Distribution of Programs between Hematological Cancer Market and Pipeline by Therapeutic Target Family
  • 5.3. First-in-Class Pipeline Programs

6. Hematological Cancer Pathophysiology and Innovation Alignment

  • 6.1. The Complexity of Signaling Networks in the Oncology
  • 6.2. Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
  • 6.3. First-in-Class Target Matrix Assessment

7. First-in-Class Target Evaluation

  • 7.1. Pipeline Programs which Target Interleukin-7 Receptor
  • 7.2. Pipeline Programs that Target Notch 2 and Notch 3
  • 7.3. Pipeline Programs that Target Focal Adhesion Kinase
  • 7.4. Pipeline Programs that Target Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1
  • 7.5. Pipeline Programs that Target Interleukin-1 Receptor Accessory Protein
  • 7.6. Pipeline Programs that Target HLA-DR
  • 7.7. Pipeline Programs that Target L-Selectin
  • 7.8. Pipeline Programs that Target Eukaryotic Translation Initiation Factor 4E

8. Strategic Consolidations

  • 8.1. Industry-Wide First-in-Class Deals
  • 8.2. Licensing Deals
    • 8.2.1. Deal by Region, Year and Value
    • 8.2.2. Deals by Stage of Development and Value
    • 8.2.3. Deals by Molecule Type, Molecular Target and Value
    • 8.2.4. Figure for Licensing Deals Valued Above $100m
  • 8.3. Co-development Deals
    • 8.3.1. Deals by Region, Year and Value
    • 8.3.2. Deals by Stage of Development and Value
    • 8.3.3. Deals by Molecule Type, Mechanism of Action and Value
    • 8.3.4. Figure for Co-development Deals Valued above $100m
  • 8.4. First-in-Class Programs Not Involved in Licensing or Co-Development Deals

9. Appendix

  • 9.1. Abbreviations
  • 9.2. Bibliography
  • 9.3. Research Methodology
  • 9.4. Secondary Research
    • 9.4.1. Marketed Product Heatmaps and Treatment Algorithm
    • 9.4.2. Pipeline Analysis
    • 9.4.3. First-in-Class Matrix Assessment
    • 9.4.4. First-in-Class Target Profiles
    • 9.4.5. Licensing and Co-development Deals
  • 9.5. Contact Us
  • 9.6. Disclaimer

List of Tables

  • Table 1: Hematological Cancers Therapeutics Market, Global, Epidemiology of Hematological Disease Severity, 2016
  • Table 2: Hematological Cancers Therapeutics Market, Global, Lymphoma, Prognostic Factors, 2016
  • Table 3: Hematological Cancers Therapeutics Market, Global, Prognostic Factors, 2016
  • Table 4: Hematological Cancer Therapeutics Market, Global, Commonly Used Chemo-Regimens
  • Table 5: Hematological Cancers Therapeutics Market, Global, Data for IL-7R Alpha as a Therapeutic Target, 2016
  • Table 6: Hematological Cancers Therapeutics Market, Global, Data for Notch 2 and Notch 3 as a Therapeutic Target, 2016
  • Table 7: Hematological Cancers Therapeutics Market, Global, Focal Adhesion Kinase as a Therapeutic Target, 2016
  • Table 8: Hematological Cancers Therapeutics Market, Global, MALT1 as a Therapeutic Target, 2016
  • Table 9: Hematological Cancers Therapeutics Market, Global, IL1RAP as a Therapeutic Target, 2016
  • Table 10: Hematological Cancers Therapeutics Market, Global, HLA-DR as a Therapeutic Target, 2016
  • Table 11: Hematological Cancers Therapeutics Market, Global, L-Selectin as a Therapeutic Target, 2016
  • Table 12: Hematological Cancers Therapeutics Market, Global, EIF-4E as a Therapeutic Target, 2016

List of Figures

  • Figure 1: Hematological Cancers Therapeutics Market, Global, Innovation Trends in Product Approvals, 1987-2012
  • Figure 2: Hematological Cancers Therapeutics Market, Global, Sales Performance of First-in-Class and Non-First-in-Class Products after Marketing Approval, 2016
  • Figure 3: Hematological Cancers Therapeutics Market, Global, Marketed Product Overview, 2016
  • Figure 4: Hematological Cancers Therapeutics Market, Global, Pipeline for Hematological Cancers by Stage of Development and Molecule Type, 2016
  • Figure 5: Hematological Cancers Therapeutics Market, Global, Pipeline for Key Hematological Cancers by Stage of Development, 2016
  • Figure 6: Hematological Cancers Therapeutics Market, Global, Pipeline for Key Hematological Cancers by Molecule Type, 2016
  • Figure 7: Hematological Cancers Therapeutics Market, Global, Pipeline for Hematological Cancers by Molecular Target, 2016
  • Figure 8: Hematological Cancers Therapeutics Market, Global, Pipeline for Key Hematological Cancers by Molecular Target, 2016
  • Figure 9: Hematological Cancers Therapeutics Market, Global, Molecular Target Category Comparison, Pipeline and Marketed Products, 2016
  • Figure 10: Hematological Cancers Therapeutics Market, Global, Molecular Target Category Comparison, Pipeline and Marketed Products, Leukemia, 2016
  • Figure 11: Hematological Cancers Therapeutics Market, Global, Molecular Target Category Comparison, Pipeline and Marketed Products, Lymphoma, 2016
  • Figure 12: Hematological Cancers Therapeutics Market, Global, Molecular Target Category Comparison, Pipeline and Marketed Products, Myeloma, 2016
  • Figure 13: Hematological Cancers Therapeutics Market, Global, Pipeline Innovation by Indication and Stage of Development, 2016
  • Figure 14: Hematological Cancers Therapeutics Market, Global, Hematological Cancer Pipeline First-in-Class and Established Molecular Targets, 2016
  • Figure 15: Hematological Cancers Therapeutics Market, Global, Leukemia Pipeline First-in-Class and Established Molecular Targets, 2016
  • Figure 16: Hematological Cancers Therapeutics Market, Global, Lymphoma Pipeline First-in-Class and Established Molecular Targets, 2016
  • Figure 17: Hematological Cancers Therapeutics Market, Global, Myeloma Pipeline First-in-Class and Established Molecular Targets, 2016
  • Figure 18: Hematological Cancers Therapeutics Market, Global, First-in-Class Products in Clinical Development, Part 1, 2016
  • Figure 19: Hematological Cancers Therapeutics Market, Global, First-in-Class Products in Clinical Development, Part 2, 2016
  • Figure 20: Hematological Cancers Therapeutics Market, Global, First-in-Class Products in Clinical Development, Part 3, 2016
  • Figure 21: Hematological Cancers Therapeutics Market, Global, First-in-Class Products in Clinical Development, Part 4, 2016
  • Figure 22: Hematological Cancers Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix, Part 1, 2016
  • Figure 23: Hematological Cancers Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix, Part 2, 2016
  • Figure 24: Hematological Cancers Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix, Part 3, 2016
  • Figure 25: Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting IL-7R Alpha, 2016
  • Figure 26: Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting Notch 2 and Notch 3, 2016
  • Figure 27: Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting Focal Adhesion Kinase, 2016
  • Figure 28: Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting MALT1, 2016
  • Figure 29: Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting IL1RAP, 2016
  • Figure 30: Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting HLA-DR, 2016
  • Figure 31: Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting L-Selectin, 2016
  • Figure 32: Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting EIF-4E, 2016
  • Figure 33: Hematological Cancers Therapeutics Market, Global, Industry-Wide Deals by Stage of Development, 2006-2014
  • Figure 34: Hematological Cancers Therapeutics Market, Global, Industry-Wide Deals by Stage of Development, 2006-2014
  • Figure 35: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Region, Year and Value, 2006-2016
  • Figure 36: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Indication and Value, 2006-2016
  • Figure 37: Hematological Cancers Therapeutic Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016
  • Figure 38: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006-2016
  • Figure 39: Hematological Cancers Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016
  • Figure 40: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Region, Year and Value, 2006-2016
  • Figure 41: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Indication, 2006-2016
  • Figure 42: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Stage of Development and Value, 2006-2016
  • Figure 43: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006-2016
  • Figure 44: Hematological Cancers Therapeutics Market, Global, Co-development Deals Valued above $100m, 2006-2016
  • Figure 45: Hematological Cancers Therapeutics Market, Global, First-in-Class Targets Not Involved in Deals, Part 1, 2016
  • Figure 46: Hematological Cancers Therapeutics Market, Global, First-in-Class Targets Not Involved in Deals, Part 2, 2016
  • Figure 47: Hematological Cancers Therapeutics Market, Global, First-in-Class Targets Not Involved in Deals, Part 3, 2016
  • Figure 48: Hematological Cancers Therapeutics Market, Global, First-in-Class Targets Not Involved in Deals, Part 4, 2016
Back to Top